COMMENTARY

Coffee Consumption and Chronic Liver Disease: The New Best Prescription?

David A. Johnson, MD

January 06, 2014

Review Article: Coffee Consumption, the Metabolic Syndrome and Non-alcoholic Fatty Liver Disease

Yesil A, Yilmaz Y
Aliment Pharmacol Ther. 2013;38:1038-1044

Study Summary

Coffee consumption is a part of daily life in most areas of the world. As such, a number of studies have evaluated the chemical composition and related effects that this enjoyable beverage may have on health and disease.

For many years, healthcare providers have advised patients to avoid excessive consumption because of a concern about caffeine dependence. Several recent studies, however, suggest that regular coffee consumption may modulate the risk for fibrosis in chronic liver disease.

Yesil and Yilmaz analyzed the experimental, epidemiologic, and clinical studies and the modulation of the metabolic syndrome and nonalcoholic fatty liver disease (NAFLD). Animal studies showed a reduction in the metabolic syndrome with improvements in glycemic and lipid regulation, as well as reductions in transaminases and proinflammatory cytokine hepatic gene expression. Other studies showed reductions in hepatic fat and collagen proinflammatory tumor necrosis factor, as well as increases in anti-inflammatory interleukins. Epidemiologic and clinical studies demonstrated a significant inverse association between coffee consumption and prevalence of metabolic syndrome, as well as a reduced risk for NAFLD.

Abstract

References

1 2

Next Section

Cite this: David A. Johnson. Coffee Consumption and Chronic Liver Disease: The New Best Prescription? - Medscape - Jan 06, 2014.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.